Please login to the form below

Not currently logged in
Email:
Password:

aflibercept

This page shows the latest aflibercept news and features for those working in and with pharma, biotech and healthcare.

Alnylam swaps Sanofi for Regeneron as R&D partner

Alnylam swaps Sanofi for Regeneron as R&D partner

Regeneron will however take the lead on eye disease candidates, a category in which it is already strong with blockbuster age-related macular degeneration (AMD) therapy Eylea (aflibercept), with Alnylam in

Latest news

More from news
Approximately 17 fully matching, plus 57 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2016 Deal Watch October 2016

    330. Ocular Therapeutics (US). Regeneron (US). Licence collaboration. Hydrogel sustained release aflibercept (Eylea) for wet macular degeneration.

  • Deal Watch March 2016 Deal Watch March 2016

    Collaboration &licence. $134. Regeneron/ Bayer. Ophthalmology combination therapy: nesvacumab (Ang2 antibody) and aflibercept (VEGF trap).

  • Interview: Beate Wieseler, IQWIG Interview: Beate Wieseler, IQWIG

    In addition fellow German firm Bayer criticised IQWiG's assessment of trial designs after the HTA body deemed data for eye drug Eylea (aflibercept) unsuitable in order to judge its

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics